BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

fallon.mcloughlin@bd.com

adam.reiffe@bd.com

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

Eric.horvath@pennmedicine.upenn.edu

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Market Opportunity
FLOW Logo
FLOW Price(FLOW)
$0.06939
$0.06939$0.06939
+3.35%
USD
FLOW (FLOW) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Eric Trump on Tuesday described Bitcoin as a “modern-day gold,” calling it a liquid store of value that can act as a hedge to real estate and other assets. Related Reading: XRP’s Biggest Rally Yet? Analyst Projects $20+ In October 2025 According to reports, the remark came during a TV appearance on CNBC’s Squawk Box, tied to the launch of American Bitcoin, the mining and treasury firm he helped start. Company Holdings And Strategy Based on public filings and company summaries, American Bitcoin has accumulated 2,443 BTC on its balance sheet. That stash has been valued in the low hundreds of millions of dollars at recent spot prices. The firm mixes large-scale mining with the goal of holding Bitcoin as a strategic reserve, which it says will help it grow both production and asset holdings over time. Eric Trump’s comments were direct. He told viewers that institutions are treating Bitcoin more like a store of value than a fringe idea, and he warned firms that resist blockchain adoption. The tone was strong at times, and the line about Bitcoin being a modern equivalent of gold was used to frame American Bitcoin’s role as both miner and holder.   Eric Trump has said: bitcoin is modern-day gold — unusual_whales (@unusual_whales) September 16, 2025 How The Company Went Public American Bitcoin moved toward a public listing via an all-stock merger with Gryphon Digital Mining earlier this year, a deal that kept most of the original shareholders in control and positioned the new entity for a Nasdaq debut. Reports show that mining partner Hut 8 holds a large ownership stake, leaving the Trump family and other backers with a minority share. The listing brought fresh attention and capital to the firm as it began trading under the ticker ABTC. Market watchers say the firm’s public debut highlights two trends: mining companies are trying to grow by both producing and holding Bitcoin, and political ties are bringing more headlines to crypto firms. Some analysts point out that holding large amounts of Bitcoin on the balance sheet exposes a company to price swings, while supporters argue it aligns incentives between miners and investors. Related Reading: Ethereum Bulls Target $8,500 With Big Money Backing The Move – Details Reaction And Possible Risks Based on coverage of the launch, investors have reacted with both enthusiasm and caution. Supporters praise the prospect of a US-based miner that aims to be transparent and aggressive about building a reserve. Critics point to governance questions, possible conflicts tied to high-profile backers, and the usual risks of a volatile asset being held on corporate balance sheets. Eric Trump’s remark that Bitcoin has taken gold’s role in today’s world reflects both his belief in its value and American Bitcoin’s strategy of mining and holding. Whether that view sticks will depend on how investors and institutions respond in the months ahead. Featured image from Meta, chart from TradingView
Share
NewsBTC2025/09/18 06:00
SEC Delays Crypto Innovation Exemptions, Citing Further Study

SEC Delays Crypto Innovation Exemptions, Citing Further Study

SEC postpones crypto innovation exemptions for blockchain products pending further analysis and congressional input.
Share
CoinLive2026/01/31 11:15
Crypto Market Crash To 6-Month Low Amid Rising Tensions Between Iran and The US

Crypto Market Crash To 6-Month Low Amid Rising Tensions Between Iran and The US

The post Crypto Market Crash To 6-Month Low Amid Rising Tensions Between Iran and The US appeared on BitcoinEthereumNews.com. Key Insights: President Trump induces
Share
BitcoinEthereumNews2026/01/31 11:02